Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

MNPR
Monopar Therapeutics Inc. Common Stock
stock NASDAQ

At Close
Dec 31, 2025 3:59:30 PM EST
64.88USD-0.300%(-0.20)285,470
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-65.07)0
After-hours
Dec 31, 2025 4:03:30 PM EST
65.30USD+0.655%(+0.43)941
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 7, 2022
07:05AM EST  Monopar to Present at the H.C. Wainwright BioConnect Conference   GlobeNewswire Inc
Dec 8, 2021
08:04AM EST  Monopar Advances Dosing Of Camsirubicin To Higher Level Than Tested In Any Previous Clinical Trial   Benzinga
08:00AM EST  Monopar Advances Dosing of Camsirubicin to Higher Level Than   GlobeNewswire Inc
Nov 12, 2021
08:19AM EST  Monopar Therapeutics Q3 EPS $(0.20) Down From $(0.15) YoY   Benzinga
08:00AM EST  First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S.Validive Phase 2b/3 VOICE Trial Cleared to Enroll in Europe andon Track for Reaching Interim in H1 2022   GlobeNewswire Inc
Nov 1, 2021
06:27AM EDT  HC Wainwright & Co. Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $9   Benzinga
Oct 27, 2021
01:54PM EDT  Monopar Therapeutics Granted Australian Patent Titled 'CLONIDINE FOR THE PREVENTION AND TREATMENT OF ADVERSE SIDE EFFECTS OF CHEMOTHERAPY'   Benzinga
08:56AM EDT  Monopar Announces First Patient Dosed In Phase 1b Trial Evaluating Camsirubicin For Advanced Soft Tissue Sarcoma   RTTNews
08:23AM EDT  Monopar Announces First Patient Dosed In Phase 1b Trial Evaluating Camsirubicin For Treatment Of Advanced Soft Tissue Sarcoma   Benzinga
08:05AM EDT  Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating   GlobeNewswire Inc
Sep 16, 2021
08:14AM EDT  Monopar Initiates Open-Label Phase 1b Clinical Trial Of Camsirubicin In Patients With Advanced Soft Tissue Sarcoma   RTTNews
08:06AM EDT  Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin In Patients With Advanced Soft Tissue Sarcoma   Benzinga
08:00AM EDT  Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating   GlobeNewswire Inc
Sep 14, 2021
11:27AM EDT  Monopar Therapeutics Sponsored Study Titled 'Camsirubicin + Pegfilgrastim to Determine MTD in ASTS' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting   Benzinga
Sep 13, 2021
08:06AM EDT  Monopar Expands Phase 2b/3 VOICE Clinical Trial To Europe   Benzinga
08:00AM EDT  -- Trial launch in Europe coincides with the Companys upcoming presentation at the European Society for Medical Oncology Congress   GlobeNewswire Inc
Sep 9, 2021
08:00AM EDT  Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler D. Robinson, MD, Chief Executive Officer,isscheduledto present a Company overview at thefollowing investor conferencesin September:   GlobeNewswire Inc
Aug 12, 2021
08:18AM EDT  Monopar Therapeutics Q2 Net Loss $2.1 Mln Or $0.17/Shr Vs Loss Of $1.4 Mln Or $0.14/Shr Last Year   RTTNews
08:09AM EDT  Monopar Therapeutics Q2 EPS $(0.17) Down From $(0.14) YoY   Benzinga
08:00AM EDT  Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021Validive Phase 2b/3 VOICE Trial on Track for Reaching Interim Analysis in H1 2022   GlobeNewswire Inc
Aug 5, 2021
08:29AM EDT  Monopar Therapeutics Reports Reached Target Number Of Clinical Sites In Phase 2b Portion Of 2b/3 Validive VOICE Trial   Benzinga
Aug 3, 2021
09:19AM EDT  Monopar Announces FDA Clearance To Proceed With Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma   RTTNews
08:00AM EDT  Monopar Announces FDA Clearance to Proceed with Camsirubicin   GlobeNewswire Inc
Jul 12, 2021
08:00AM EDT  Monopar Appoints Octvio Costa, MD, as Chief Medical   GlobeNewswire Inc
Jun 24, 2021
08:03AM EDT  Monopar To Present Results From Analysis Of Oropharyngeal Cancer Patients In Completed Phase 2 Validive Trial At MASCC/ISOO   Benzinga
08:00AM EDT  Monoparto Present Results from Analysis of   GlobeNewswire Inc
Jun 3, 2021
12:24PM EDT  Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings   Benzinga
08:09AM EDT  Monopar Announces New Drug Candidate, MNPR-202; Says Enters Into Collaboration Agreement With National University Of Singapore For Preclinical Evaluation In Cancer   Benzinga
08:00AM EDT  MonoparAnnounces New Drug Candidate, MNPR-202, and   GlobeNewswire Inc
Jun 1, 2021
04:05PM EDT  MonoparTherapeutics Expands Leadership Team with   GlobeNewswire Inc
May 26, 2021
08:22AM EDT  Monopar Therapeutics, NorthStar Medical Report Filing Of Provisional Composition Of Matter Patent Titled 'Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical'   Benzinga
08:00AM EDT  Monopar and NorthStar Announce Filing of Composition of Matter   GlobeNewswire Inc
May 24, 2021
08:11AM EDT  Monopar, NorthStar Announce Patent Filing On Radiopharmaceutical Discovery   Benzinga
08:00AM EDT  Monoparand NorthStar Announce Patent Filing on   GlobeNewswire Inc
May 13, 2021
05:22PM EDT  Monopar Therapeutics Q1 EPS $(0.16) Down From $(0.10) YoY   Benzinga
Mar 30, 2021
10:13AM EDT  Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer   Benzinga
07:37AM EDT  Monopar Therapeutics Highlights Publication Of Study Titled 'Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography'   Benzinga
07:30AM EDT  Monopars uPA Antibody Fragment Radiotracer Shows   GlobeNewswire Inc
Mar 25, 2021
08:12AM EDT  Monopar Therapeutics Q4 EPS $(0.19) Down From $(0.13) YoY   Benzinga
08:00AM EDT  Validive Phase 2b/3 VOICE Clinical Trial CommencedCamsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021MNPR-101-Conjugate Data Published inEuropean Journal of Cancer   GlobeNewswire Inc
Mar 2, 2021
07:41AM EST  Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery   Benzinga
07:30AM EST  Monopar Partners with Seasoned Medtech Executive to Explore the   GlobeNewswire Inc
Feb 24, 2021
07:30AM EST  MonoparTherapeutics Inc. (Nasdaq: MNPR),a clinical-stagebiopharmaceuticalcompany primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients,todayannounced that Chandler D. Robinson, MD, Chief Executive Officer, is planning to present a Company overview at the following investor conferences in March:   GlobeNewswire Inc
Feb 18, 2021
07:00AM EST  Monopar Expands Clinical Team with Appointment of Laura Kelly as   GlobeNewswire Inc
Feb 16, 2021
07:43AM EST  Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer   Benzinga
07:30AM EST  Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE   GlobeNewswire Inc
Feb 15, 2021
11:41AM EST  Finding Consistency In An Unprecedented Market   Benzinga
Feb 11, 2021
02:55PM EST  Mid-Afternoon Market Update: Wall Street Stocks Tumble; Crude Oil Down Over 1%   Benzinga
11:26AM EST  Mid-Morning Market Update: RCM Technologies Shares Spike Higher, Even As Walt Disney Prepares to Announce Q1 Results   Benzinga
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
09:50AM EST  Shares of Monopar Therapeutics Inc. (MNPR) are up more than 60% Thursday morningThe company announced publication of a peer-reviewed study showing the potential utility of MNPR-101, the company's proprietary humanized uPAR antibody, as a uPAR imaging agent to improve surgical outcomes in bladder cancer.   RTTNews
07:30AM EST  MonoparAnnounces Publication Demonstrating Potential   GlobeNewswire Inc
Feb 9, 2021
07:07AM EST  Monopar Says Co Issuance Of Patent Covering Composition Of Matter For MNPR-101 In Canada   Benzinga
07:00AM EST  Monopar Announces Issuance of Patent Covering Composition of   GlobeNewswire Inc
Jan 28, 2021
03:02PM EST  Mid-Afternoon Market Update: Dow Surges 500 Points; Property Solutions Acquisition Shares Spike Higher   Benzinga
12:07PM EST  Mid-Day Market Update: Silver Surges 5%; AMC Entertainment Shares Slide   Benzinga
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2021   Benzinga
09:51AM EST  Shares of Monopar Therapeutics Inc. (MNPR) are currently gaining over 55% despite no stock-related news to drive the shares.   RTTNews
07:10AM EST  Roth Capital Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $49   Benzinga
Dec 22, 2020
08:37AM EST  Monopar Announces Issuance Of U.S. Patent Covering Compositions Of Matter For A Novel Family Of Camsirubicin Analogs   Benzinga
08:30AM EST  -Issued patent expands and strengthens Monopars existing camsirubicin IP portfolio-Phase 2 initiation for camsirubicin in advanced soft tissue sarcoma remains on track for early 2021   GlobeNewswire Inc
Dec 10, 2020
08:32AM EST  Monopar, NorthStar Announce Selection Of uPRIT Candidate For Potential Treatment Of Severe COVID-19   Benzinga
08:30AM EST  Monopar and NorthStar Announce Selection of uPRIT Candidate for   GlobeNewswire Inc
Dec 8, 2020
08:33AM EST  Monopar Reports Initiation Of Phase 2b/3 VOICE Trial To Evaluate Validive For Prevention Of Chemoradiotherapy-Induced Severe Oral Mucositis In Oropharyngeal Cancer   Benzinga
08:30AM EST  There are currently no FDA-approved drugs to prevent or treat chemoradiotherapy-induced SOM   GlobeNewswire Inc
Nov 12, 2020
09:21AM EST  Monopar Therapeutics Q3 EPS $(0.15) Down From $(0.08) YoY   Benzinga
09:15AM EST  Validive Phase 2b/3 Clinical Trial on Track to Start Before Year-endIssuance of New Patents For ValidiveCamsirubicin Phase 2 Clinical Trial to Start Late 2020/Early 2021   GlobeNewswire Inc
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 9, 2020
08:45AM EST  Monopar Announces Issuance Of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive   Benzinga
08:30AM EST  Monopar Announces Issuance of New Patents Broadening Protections   GlobeNewswire Inc
Nov 3, 2020
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Sep 24, 2020
10:40AM EDT  Maxim Group Initiates Coverage On Monopar Therapeutics with Buy Rating, Announces Price Target of $11   Benzinga
Sep 14, 2020
08:30AM EDT  Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced that Chandler D. Robinson, MD, Chief Executive Officer, will present a corporate update at the H.C. Wainwright 22nd Annual Global Investment Conference, Healthcare & Biotech Track. The conference will be held virtually.   GlobeNewswire Inc
Sep 9, 2020
08:33AM EDT  Monopar And NorthStar Radioisotopes Collaborate With Texas Lung Injury Institute For Testing Of Novel Potential Therapeutic For Severe COVID-19   Benzinga
08:30AM EDT  Monopar and NorthStar Collaborating with Texas Lung Injury   GlobeNewswire Inc
Aug 19, 2020
10:25AM EDT  Shares of Monopar Therapeutics Inc. (MNPR) jumped over 10% on Wednesday morning after the company said it has partnered with Aragen for testing a potential treatment for COVID-19.   RTTNews
08:39AM EDT  Monopar, NorthStar Partner With Aragen For Testing Of Potential Therapeutic For Severe COVID-19   RTTNews
08:31AM EDT  Monopar and NorthStar Partner with Aragen for Testing of 'Novel Potential Therapeutic for Severe COVID-19'   Benzinga
08:30AM EDT  Monopar and NorthStar Partner with Aragen for Testing of Novel   GlobeNewswire Inc
Aug 17, 2020
09:05AM EDT  What To When You Start The Day In The Red   Benzinga
Aug 12, 2020
04:45PM EDT  04:45 Wednesday, August 12, 2020   RTTNews
09:57AM EDT  Shares of Monopar Therapeutics Inc. (MNPR) are gaining more than 62 percent or $4.63 in Wednesday's morning trade at $12.02.   RTTNews
08:40AM EDT  Monopar Therapeutics Outlines Plan To Develop Test To Potentially Triage Coronavirus Patients Into Those Likely Versus Unlikely To Progress To Severe Respiratory Failure   Benzinga
08:30AM EDT  Monopar Announces Plan to Advance Development of Novel Triage Test   GlobeNewswire Inc
Aug 10, 2020
08:49AM EDT  Monopar And NorthStar Partner With IsoTherapeutics For The Manufacturing Of Potential Therapeutic For Severe COVID-19   Benzinga
08:30AM EDT  Monopar and NorthStar Partner with IsoTherapeutics for the   GlobeNewswire Inc
Aug 6, 2020
04:45PM EDT  Monopar Therapeutics Q2 EPS $(0.14), Reports Cash And Equivalents Of $12.5M As Of Jun. 30   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC